When Is FDA Form 2252 Required? (w/Examples) + FAQs

FDA Form 2252 is required when manufacturers submit annual reports for approved New Drug Applications (NDAs), Abbreviated New Drug Applications (ANDAs), and Biologics License Applications (BLAs). Under 21 CFR 314.81(b)(2), pharmaceutical and biologics manufacturers must file this transmittal form within 60 days of each U.S. approval anniversary date, accompanying the mandatory annual report that tracks safety, effectiveness, and postmarketing study progress.

The requirement exists because Section 506B of the Federal Food, Drug, and Cosmetic Act mandates ongoing surveillance of approved drug products after they enter the market. Failure to submit Form 2252 with annual reports can trigger enforcement actions including application withdrawal, civil monetary penalties exceeding $250,000 per violation, and increased FDA scrutiny of future submissions. According to recent FDA enforcement data, approximately 15% of all NDA holders receive compliance warnings annually for late or incomplete annual report submissions, with Form 2252 errors representing a significant portion of these violations.

What you’ll learn from this article:

🔍 The exact regulatory triggers that mandate Form 2252 filing under federal law and when exemptions apply

📋 Field-by-field completion guidance for all 14 sections of the form, including common pitfalls that delay processing

⚖️ Real-world consequences of non-compliance, from warning letters to product recalls and license revocations

🌐 Foreign manufacturer requirements for U.S. agent designation and cross-border submission protocols

✅ Proven strategies to avoid the top 10 rejection reasons and ensure acceptance on first submission

Understanding FDA Form 2252: The Transmittal Foundation

FDA Form 2252 serves as the official transmittal document for annual reports concerning drugs and biologics for human use. The form acts as a cover sheet that identifies the application type, summarizes the report contents, and certifies compliance with federal reporting requirements.

The form contains 14 distinct fields that capture critical information. Fields 1 through 3 identify the regulatory center (CDER or CBER), application type, and application number. Fields 4 and 5 capture applicant or U.S. agent contact information. Fields 6 through 9 document the report type, product names, additional application numbers if applicable, and the reporting period dates.

Section 10 contains a detailed checklist for NDA and ANDA report requirements, while Section 11 addresses BLA-specific postmarketing study information. Fields 12 through 14 capture the responsible official’s information and signature, which legally binds the applicant to the accuracy of the submission.

The form underwent significant revisions in 2022 to align with electronic submission standards. The current version requires completion in fillable PDF format for electronic submissions through the Electronic Submission Gateway (ESG).

Who Must File Form 2252: Application Types and Holders

Any entity holding an approved NDA, ANDA, or BLA must file Form 2252 annually. This mandatory requirement applies regardless of whether the product is actively marketed or temporarily discontinued.

New Drug Application Holders

Companies with approved NDAs must submit Form 2252 each year within 60 days of their U.S. approval anniversary. This includes both prescription and over-the-counter drugs that received approval through the full NDA pathway demonstrating safety and effectiveness through clinical trials.

The requirement applies to the original NDA holder even if manufacturing has been transferred or licensed to another entity. If the NDA holder changes through corporate acquisition or asset sale, the new holder assumes the annual reporting obligation from the transfer date.

Abbreviated New Drug Application Holders

ANDA holders face identical annual reporting requirements as NDA holders. Generic drug manufacturers must file Form 2252 within 60 days of their ANDA approval anniversary, regardless of market share or sales volume.

The form must accompany reports containing distribution data, manufacturing changes, and any new safety information. According to FDA eCTD validation criteria, ANDA submissions without Form 2252 receive automatic rejection with a “High” severity designation, halting the review process entirely.

Biologics License Application Holders

BLA holders submit Form 2252 under 21 CFR 601.70, which governs annual progress reports of postmarketing studies. This includes manufacturers of vaccines, blood products, gene therapies, and cellular products.

The reporting obligation extends to products approved under accelerated approval pathways. These manufacturers must document progress on postmarketing requirements designed to verify clinical benefit, making Form 2252 submission particularly critical for continued market authorization.

The Annual Report Requirement: Timing and Contents

The annual report requirement stems from federal regulations that mandate ongoing monitoring of approved products. Understanding the timing and content requirements prevents costly compliance failures.

The 60-Day Anniversary Rule

Applicants must submit their annual report within 60 days of the U.S. approval anniversary date. The anniversary date is the date FDA issued the approval letter, not the date the company received it or began commercial distribution.

For example, if FDA approved an NDA on March 15, 2020, the applicant must submit the annual report by May 14 each subsequent year. Missing this deadline by even one day constitutes a regulatory violation that FDA can cite during inspections.

The reporting period covered by each annual report runs from the previous anniversary date through the current anniversary date. Companies must include all relevant information obtained during this 12-month window, even if the information arrived on the final day of the reporting period.

Mandatory Report Components

The annual report must contain specific elements listed in the regulations. For NDAs and ANDAs, 21 CFR 314.81(b)(2) requires nine distinct information categories, each documented in Section 10 of Form 2252.

Companies must provide a summary of significant new information affecting safety, effectiveness, or labeling. This includes any data suggesting previously unknown risks or changes to the benefit-risk profile.

Distribution data requirements mandate reporting the quantity distributed to all channels, including distributors and wholesalers. For products with authorized generic versions, applicants must separately identify distribution volumes for both the reference listed drug and the authorized generic, along with the National Drug Code (NDC) numbers for each product.

Labeling submissions must include currently used professional labeling, patient brochures, package inserts, and representative samples of carton and container labels. This ensures FDA maintains current copies of all patient-facing materials.

Chemistry, manufacturing, and controls changes not requiring prior approval supplements must be fully described. This captures the cumulative effect of minor manufacturing modifications that individually fall below the threshold for supplemental applications.

Field-by-Field Completion Guide

Completing Form 2252 accurately requires attention to specific field requirements and formatting standards. Each field serves a distinct regulatory purpose.

Fields 1-3: Application Identification

Field 1 requires selection of the appropriate FDA center. Check CDER for drugs or CBER for biological products. This determines the review division that receives the submission.

Field 2 identifies the application type. Select NDA, ANDA, or BLA based on the original approval pathway. For combination products reviewed under different application types, submit separate Form 2252 documents for each application number.

Field 3 requires the complete application number in the format assigned by FDA. For CBER BLAs, include both the application number and supplement number if known. Entering an incorrect application number triggers immediate rejection during electronic validation.

Fields 4-5: Applicant and U.S. Agent Information

Fields 4 and 5 capture different information depending on whether the applicant resides in the United States. U.S. applicants enter their own name and phone number in these fields.

Foreign applicants must list their authorized U.S. agent information in Fields 4 and 5. Under 21 CFR 314.50(a)(5), foreign entities without a U.S. place of business must designate a U.S. agent who resides or maintains a physical business location within the United States.

The U.S. agent cannot be a mailbox service, answering service, or location where the agent is not physically present. The agent assumes responsibility for receiving FDA communications, responding to agency questions, and assisting with inspection scheduling.

For biologics, Field 4 must contain the name of the person or legal entity to whom the license was issued. If the license holder is a foreign corporation, the U.S. agent information still appears in Fields 4 and 5, with the actual license holder identified in the report body.

Field 6: Report Type Selection

Field 6 identifies the specific type of report being submitted. The most common entry is “Annual Report,” but applicants may also submit periodic reports for postmarketing requirements, safety updates, or other purposes using Form 2252 as the transmittal.

When submitting reports under the Right to Try Act, applicants use Form 2252 to transmit the annual summary of expanded access use. This leverages the same transmittal infrastructure for different reporting obligations.

Field 7: Product Names

Field 7 requires both the proprietary name (brand name) and established name (generic or chemical name) for the product. If the product lacks a proprietary name, such as generic drugs marketed under their established names, enter the established name twice or write “None” for proprietary name.

For combination products containing multiple active ingredients, list all established names separated by forward slashes or semicolons. Accuracy here prevents confusion when FDA staff route the submission to the appropriate scientific reviewers.

Field 8: Additional Application Numbers

Field 8 captures additional NDA, ANDA, or BLA numbers if any part of the report applies to multiple applications. This situation arises when companies hold multiple applications for the same active ingredient in different strengths or formulations.

For example, a manufacturer holding three NDAs for 10mg, 20mg, and 50mg tablets of the same drug may submit a single annual report covering all three strengths. List the primary application number in Field 3 and enter the additional application numbers in Field 8.

Use the continuation page if the report covers more than three additional applications. Each additional application must be individually identified with its complete application number.

Field 9: Reporting Period Dates

Field 9 requires the beginning and end dates encompassing the reporting period. For annual reports, this spans exactly 12 months from the previous anniversary date through the current anniversary date.

Enter dates in MM/DD/YYYY format. The end date must match the U.S. approval anniversary date. Mismatched dates suggest the report covers the wrong time period, potentially leading to rejection.

Field 10: NDA/ANDA Report Information Table

Section 10 contains a detailed table listing nine categories of required information. Under the “Identification” column, applicants must enter the electronic file name or volume number for paper submissions, along with the page numbers where each information type appears.

If nothing exists to report for a specific category, enter “None” under Identification. Leaving the field blank creates ambiguity about whether information is absent or was accidentally omitted.

The nine categories include summary of significant new information, distribution data, labeling, chemistry/manufacturing/controls changes, nonclinical laboratory studies, clinical data, status reports of open postmarketing requirements and commitments, status of other open postmarketing studies, and an optional log of outstanding regulatory business.

For postmarketing requirements (PMRs) and commitments (PMCs), applicants increasingly use Form FDA 3989 to report status information. When Form 3989 is included in the annual report at Section 1.13.12 of the electronic Common Technical Document (eCTD), note this in Field 10.g by writing “Form FDA 3989 included in Section 1.13.12.”

Field 11: BLA Report Information

Field 11 applies exclusively to BLA holders. Check the box if the submission includes status reports of postmarketing study commitments required under 21 CFR 601.70.

BLA annual reports focus heavily on postmarketing studies concerning clinical safety, efficacy, pharmacology, and nonclinical toxicology. These include studies FDA required as a condition of accelerated approval and pediatric studies mandated under the Pediatric Research Equity Act.

Unlike NDA/ANDA holders who complete the Field 10 table, BLA holders use Field 11 as a simplified checkbox system. The detailed study information appears in the report body rather than being itemized on the form itself.

Fields 12-14: Responsible Official and Signature

Fields 12 and 13 capture the name, title, and street address of the responsible official or authorized U.S. agent to whom FDA should direct correspondence regarding the annual report. This person certifies compliance with applicable laws and regulations.

The responsible official must have authority to legally bind the company. Typical signatories include the Chief Executive Officer, President, Vice President of Regulatory Affairs, or individuals with explicit written delegation of signature authority.

Field 14 requires a handwritten signature for paper submissions or an electronic signature meeting 21 CFR Part 11 requirements for electronic submissions. The signature date must not precede the report’s preparation date.

For foreign applicants without U.S. residence or business operations, an attorney, agent, or other authorized official who resides or maintains a place of business within the United States must sign Field 14, as mandated by 21 CFR 314.50(a)(5).

Electronic Submission Requirements and eCTD Format

Modern FDA submissions occur almost exclusively through electronic pathways. Understanding electronic submission requirements prevents technical rejections.

The eCTD Mandate

Under Section 745A of the Federal Food, Drug, and Cosmetic Act, applicants must submit NDAs, ANDAs, BLAs, and related reports in electronic Common Technical Document (eCTD) format. Annual reports fall under this mandate.

The eCTD organizes content into five modules, with Form 2252 residing in Module 1 as a regional administrative document. The form must be in fillable PDF format with a file name following FDA’s naming conventions.

FDA currently supports eCTD versions 3.2.2 and 4.0, with version 4.0 becoming available for new applications beginning September 16, 2024. Applicants must check the FDA Data Standards Catalog for the supported versions before submission.

Form Validation Criteria

FDA’s electronic gateway performs automated validation on all submissions. Form 2252 undergoes specific validation checks that can result in immediate rejection.

Validation error 7 in the FDA eCTD validation criteria specifically addresses fillable form requirements. Submissions lacking the appropriate fillable form 356h, 2252, or 1571 receive a “High” severity error, and FDA returns the submission without review.

The application type and number listed on Form 2252 must exactly match the application type and number in the us-regional.xml file. Inconsistencies between these elements trigger validation error 5, requiring resubmission with corrected information.

From January through September 2024, FDA rejected 81 ANDA applications for fillable form errors. The agency requires Form 2252 for annual report submissions and Form 356h for all other ANDA submissions. Submitting the wrong form type causes immediate rejection.

Electronic Submission Gateway Process

Applicants transmit eCTD submissions through the Electronic Submission Gateway (ESG), which requires prior account setup. Companies must obtain an ESG account by designating an account administrator who completes the registration process.

The receipt date for electronic submissions is established tentatively when the submission arrives through ESG, then permanently when FDA determines the submission is technically acceptable. Technical acceptability means the agency can open, process, and archive the files.

If validation errors prevent processing, FDA sends a notification describing the specific errors. Applicants must correct the errors and resubmit using the same sequence number. The corrected submission receives a new receipt date based on when FDA successfully processes the resubmission.

Critical Scenarios Requiring Form 2252

Understanding when Form 2252 becomes mandatory prevents inadvertent violations. Several distinct scenarios trigger the filing requirement.

Scenario 1: Standard Annual Report Submission

Every NDA, ANDA, and BLA holder encounters this scenario annually. A pharmaceutical company with an NDA approved on June 1, 2020, must submit Form 2252 by July 31 each year (within 60 days of the June 1 anniversary). The form accompanies the annual report containing safety updates, distribution data, labeling changes, and manufacturing modifications from the prior 12 months.

Scenario 2: Products Under Accelerated Approval

Products approved under accelerated approval provisions carry postmarketing requirements to verify and describe clinical benefit. These requirements represent a condition of approval. Form 2252 serves as the annual tracking mechanism for PMR progress.

An oncology drug approved under accelerated approval based on tumor response rates must conduct a postmarketing trial measuring overall survival. Each year until trial completion, the sponsor files Form 2252 documenting enrollment progress, any protocol amendments, interim safety findings, and projected timeline to final data readiness.

Scenario 3: Foreign Manufacturer with U.S. Agent

A German pharmaceutical manufacturer holding an NDA for a cardiovascular drug must designate a U.S. agent with a physical office in the United States. The U.S. agent’s responsibilities include responding to FDA questions, assisting with inspection scheduling, and receiving agency communications.

When filing Form 2252, the German manufacturer enters the U.S. agent’s name, phone number, and address in Fields 4 and 5. The U.S. agent signs Field 14 on behalf of the foreign license holder. If FDA needs to contact the manufacturer about the annual report, the agency communicates with the U.S. agent, which is legally equivalent to communicating directly with the foreign entity.

Postmarketing Requirements and Commitments Reporting

Form 2252 plays a central role in tracking postmarketing studies and clinical trials. Section 506B of the FD&C Act mandates annual reporting on these commitments.

Understanding PMRs vs. PMCs

Postmarketing requirements (PMRs) are studies FDA requires applicants to conduct under statute or regulation. These include accelerated approval clinical benefit studies, deferred pediatric studies under PREA, and studies required under the Animal Efficacy Rule.

Under the FDA Amendments Act of 2007, FDA gained authority to require postmarketing studies to assess known serious risks, signals of serious risk, or unexpected serious risks when data indicate potential for serious harm.

Postmarketing commitments (PMCs) are studies applicants agree to conduct but are not legally required to perform. These typically address questions that emerged during the approval review but were not significant enough to delay approval or mandate as conditions.

The critical distinction affects enforcement. If an applicant fails to complete a PMR, FDA can withdraw the product’s approval. For PMCs, FDA cannot withdraw approval but can publicly disclose the applicant’s failure to fulfill commitments, creating reputational and market consequences.

Status Reporting Requirements

For each PMR and 506B-reportable PMC, applicants must report annual status using standardized terminology. The status categories include Pending, Ongoing, Delayed, Submitted, Terminated, Fulfilled, and Released.

“Pending” means the study has not yet been initiated. “Ongoing” indicates active conduct with enrollment or data collection proceeding. “Delayed” signals the study timeline has slipped beyond the original projected dates.

“Submitted” means the final study report has been provided to FDA but the agency has not yet issued a fulfillment determination. “Terminated” indicates the study was discontinued before completion. “Fulfilled” and “Released” represent closed status where FDA has formally accepted the study.

Field 10.g of Form 2252 addresses status reports of open PMRs and PMCs. Applicants enter “None” if no open PMRs or 506B-reportable PMCs exist, or identify where the status information appears in the annual report.

Form FDA 3989 Integration

Many applicants now use Form FDA 3989 to report PMR/PMC status information instead of narrative descriptions. Form 3989 provides a standardized template capturing applicant name, product name, application number, approval date, and individual study details.

When Form 3989 is submitted as Section 1.13.12 of the eCTD annual report, applicants note this in Field 10.g by writing “Form FDA 3989 included in Section 1.13.12.” This satisfies the reporting requirement under 21 CFR 314.81(b)(2)(vii) for NDAs and ANDAs or 21 CFR 601.70 for BLAs.

For BLA holders, checking the box in Field 11.a indicates that Form 3989 is included as the annual status report. This replaces company-derived narrative status reports with the standardized form format.

Distribution Data and Authorized Generics

Form 2252 requires specific documentation of product distribution volumes, including special provisions for authorized generic drugs.

Standard Distribution Reporting

Field 10.b of Form 2252 addresses distribution data requirements under 21 CFR 314.81(b)(2)(ii). Applicants must report the quantity of drug product distributed under the approved application, including amounts distributed to distributors, wholesalers, and other intermediate handlers.

The distribution data helps FDA track product availability, detect shortages, and understand market dynamics. This information becomes particularly important when safety signals emerge and the agency needs to assess how many patients may be affected.

Applicants indicate whether distribution data for an authorized generic drug product is included. The body of the annual report must contain the specific distribution volumes with NDC numbers for both the reference listed drug and any authorized generic versions.

Authorized Generic Provisions

An authorized generic is a drug marketed by the NDA holder or with the NDA holder’s permission under a different label, typically at a lower price point to compete with generic versions from ANDA holders. The drug itself remains identical to the reference listed drug.

Under 21 CFR 314.81(b)(2)(ii)(b), applicants must provide detailed information about authorized generics, including the proprietary and established names, NDC numbers, quantities distributed, and the dates distribution began and ended.

This requirement emerged from concerns that authorized generics affect the market dynamics and economic incentives underlying the Hatch-Waxman Act’s generic drug provisions. By tracking authorized generic distribution separately, FDA can assess their impact on competition and exclusivity periods.

Manufacturing and Controls Changes

Annual reports must document certain manufacturing changes that do not require prior approval supplements. Form 2252 Field 10.d addresses these chemistry, manufacturing, and controls modifications.

Reportable Changes Categories

Under 21 CFR 314.70, postapproval manufacturing changes fall into three reporting categories based on their potential to adversely affect product identity, strength, quality, purity, or potency.

Major changes require a prior approval supplement before implementing the change or distributing product made with the modification. Moderate changes require either a prior approval supplement or a Changes Being Effected in 30 days (CBE-30) supplement depending on specific criteria. Minor changes can be described in the annual report without prior notification.

Examples of annual-reportable changes include relaxing an in-house acceptance criterion within approved limits, implementing an editorial change to the application, making minor equipment changes that don’t alter operating principles, and adding another site for packaging or labeling without formula modifications.

Documentation Requirements

For each manufacturing or controls change reported in the annual report, applicants must provide a full description listed by date. The description should include the name of affected drug products, reference to previously approved grouped supplements if applicable, and details of studies or tests performed to assess the change’s effect.

Executed batch records, standard operating procedures, and data from validation studies should be maintained on file and made available to FDA inspectors upon request. The annual report description must contain enough detail for FDA to determine whether the appropriate reporting category was used.

Field 10.d of Form 2252 identifies where in the annual report the manufacturing changes section appears. This might be an electronic file name like “Module3_Section3.2.P.3.5_ManufacturingChanges.pdf” or a page range for paper submissions.

Common Mistakes to Avoid

Certain errors occur repeatedly in Form 2252 submissions, causing delays and compliance issues. Learning from common mistakes improves submission quality.

Mistake 1: Missing or Incorrect Application Number

Error: Entering an application number with transposed digits, omitting leading zeros, or listing an incorrect application type.

Consequence: Electronic validation immediately rejects the submission with a “High” severity error. FDA does not review the content until the corrected submission arrives, delaying the compliance date and potentially causing the applicant to exceed the 60-day deadline.

Prevention: Verify the exact application number from the original FDA approval letter. For CBER biologics, include both application and supplement numbers. Double-check Field 3 against the us-regional.xml file to ensure identical values.

Mistake 2: Incomplete U.S. Agent Information

Error: Foreign applicants listing incomplete U.S. agent contact details, using mailbox services or answering services as the U.S. agent address, or failing to update agent information when the agent changes.

Consequence: FDA cannot effectively communicate with the applicant regarding the annual report. Important agency requests or questions may go unanswered. In severe cases, FDA may deem the application incomplete and refuse future submissions until a compliant U.S. agent is designated.

Prevention: Ensure the U.S. agent maintains a physical business location in the United States where representatives are present during business hours. Update Form 2252 Fields 4-5 whenever agent changes occur. Confirm the U.S. agent has confirmed their designation through FDA’s automated verification system.

Mistake 3: Wrong Form Type for Submission

Error: Submitting Form 356h instead of Form 2252 for an annual report, or submitting Form 2252 for a new application or supplement.

Consequence: Automatic rejection during eCTD validation. Between January and September 2024, FDA rejected 81 ANDA applications for fillable form errors. The submission receives no review until resubmitted with the correct form type.

Prevention: Form 2252 is exclusively for transmitting annual reports and certain periodic reports. All other NDA/ANDA/BLA submissions require Form 356h. Before finalizing the eCTD package, verify the form type matches the submission type.

Mistake 4: Mismatched Reporting Period Dates

Error: Listing a reporting period in Field 9 that does not align with the U.S. approval anniversary date, or entering dates that span more or less than 12 months.

Consequence: FDA questions whether the report covers the correct time period. The agency may issue an information request asking for clarification or corrected dates, delaying review and acceptance.

Prevention: Calculate the reporting period by identifying the exact approval anniversary date from the approval letter. The period runs from the previous anniversary through the current anniversary. Enter dates in MM/DD/YYYY format with the end date matching the anniversary.

Mistake 5: Leaving “None” Fields Blank

Error: Leaving identification fields blank in the Field 10 table when there is nothing to report for a particular category, creating ambiguity about whether information is absent or was accidentally omitted.

Consequence: FDA cannot distinguish between intentional non-reporting (nothing to report) and accidental omission (forgot to include information). This triggers information requests and extends review timelines.

Prevention: For any category where no information exists, explicitly enter “None” in the Identification column. This clearly communicates that the applicant reviewed the requirement and determined nothing existed for that specific category during the reporting period.

Mistake 6: Outdated Form Version

Error: Using an expired version of Form 2252 that no longer meets current FDA standards or eCTD validation requirements.

Consequence: Electronic validation may reject the submission. Even if the submission initially processes, FDA may later request resubmission with the current form version, creating additional work and compliance risk.

Prevention: Download Form 2252 directly from the FDA Forms webpage immediately before preparing each submission. Verify the form’s expiration date appears in the footer. Do not maintain local archives of old form versions.

Mistake 7: Inconsistent Product Names

Error: Listing product names in Field 7 that do not exactly match the approved names in the application, using abbreviations, or omitting the established name.

Consequence: FDA reviewers may have difficulty routing the submission to the correct scientific staff. Product name mismatches can trigger questions about whether the annual report addresses the correct approved product.

Prevention: Copy product names directly from the approval letter. Include both proprietary and established names exactly as approved. If multiple strengths exist, list all strengths or reference them appropriately.

Mistake 8: Missing PMR/PMC Status Updates

Error: Failing to provide status updates for open postmarketing requirements or commitments, or using non-standard status terminology that does not match FDA’s defined categories.

Consequence: Violation of Section 506B reporting requirements. FDA tracks PMR/PMC compliance through an internal database. Missing status reports can lead to compliance letters, public disclosure of non-compliance, and in severe cases, consideration of approval withdrawal for unfulfilled PMRs.

Prevention: Maintain an internal tracking system for all PMRs and PMCs. Before preparing the annual report, update the status of each commitment using only FDA’s standardized terminology (Pending, Ongoing, Delayed, Submitted, Terminated, Fulfilled, Released). Consider using Form FDA 3989 for consistent formatting.

Mistake 9: Improper Signature Authority

Error: Having the form signed by someone without legal authority to bind the company, using an outdated signature after personnel changes, or failing to obtain a compliant electronic signature meeting 21 CFR Part 11 requirements.

Consequence: The submission lacks proper legal certification. FDA may question the validity of the submission and require resubmission with an authorized signature. In enforcement contexts, improperly signed submissions may not be considered valid filings.

Prevention: Confirm the signatory holds a position with explicit authority to legally bind the company (CEO, President, VP Regulatory Affairs, or documented delegate). For electronic submissions, implement a 21 CFR Part 11-compliant electronic signature system that captures identity authentication and document integrity.

Mistake 10: Distribution Data Calculation Errors

Error: Reporting distribution volumes that do not account for returns, failing to separately identify authorized generic distribution, or using inconsistent units of measure.

Consequence: FDA relies on distribution data for shortage monitoring and safety assessments. Inaccurate data can lead to flawed policy decisions. During inspections, FDA may compare reported distribution data against manufacturing records, and discrepancies trigger warning letters for data integrity issues.

Prevention: Implement a robust system for tracking distribution to all channels including distributors, wholesalers, and direct customers. Account for product returns when calculating net distribution. Separately track and report authorized generic volumes with distinct NDC numbers. Use consistent units across reporting periods.

Do’s and Don’ts for Form 2252 Compliance

Following established best practices ensures smooth submission processing and regulatory compliance.

Do’s

Do verify application numbers before submission. Always cross-reference the application number in Field 3 against the original approval letter. A single digit error triggers immediate rejection, wasting time and potentially causing missed deadlines.

Do maintain a submission calendar. Create a perpetual calendar tracking each application’s U.S. approval anniversary date and the corresponding 60-day filing deadline. Set reminders 90 days before the deadline to begin compiling annual report content, ensuring adequate time for review and correction before submission.

Do use current fillable forms. Download Form 2252 from FDA’s official forms website immediately before each submission. Form versions change as FDA updates electronic submission standards. Using outdated forms creates unnecessary compliance risk when current versions are freely available.

Do document all PMR/PMC status changes. Maintain detailed records of postmarketing study progress including enrollment milestones, protocol amendments, interim results, and timeline modifications. This documentation supports accurate status reporting and provides evidence of good faith compliance efforts if FDA questions study progress.

Do keep execution records for manufacturing changes. Although manufacturing changes reported in annual reports do not require prior FDA approval, executed batch records, validation protocols, and stability data should be maintained on file. FDA inspectors regularly audit these records to verify that changes were implemented as described and did not adversely affect product quality.

Do engage qualified U.S. agents for foreign operations. If operating as a foreign manufacturer, select a U.S. agent with pharmaceutical industry experience who understands FDA communication protocols. The U.S. agent serves as the primary FDA contact point, making their competence critical to maintaining good regulatory standing.

Do validate eCTD packages before submission. Use FDA’s validation software to check eCTD packages for technical errors before transmitting through ESG. Catching validation errors pre-submission prevents rejection and eliminates the resubmission cycle.

Don’ts

Don’t wait until the deadline to begin preparation. Annual reports require compiling data from multiple departments including regulatory affairs, quality assurance, manufacturing, and pharmacovigilance. Starting compilation 30 days or less before the deadline creates rushed work prone to errors and provides insufficient time for senior management review.

Don’t submit without senior review. The signature on Form 2252 legally certifies compliance with federal requirements. Before submission, ensure senior management and legal counsel have reviewed the annual report contents, especially sections addressing adverse events, manufacturing deviations, or PMR/PMC delays that could attract regulatory scrutiny.

Don’t reuse prior year templates without updates. While templates ensure consistency, blindly copying prior year language without updating for current information creates serious compliance issues. Each annual report must reflect information from the specific reporting period, including new safety data, updated distribution volumes, and current PMR/PMC status.

Don’t ignore eCTD validation errors. If FDA’s electronic gateway returns validation errors, address every error completely before resubmission. Attempting to work around validation errors or submitting with minor unfixed issues prevents FDA from processing the submission and compounds compliance problems.

Don’t mix application types on one Form 2252. Submit separate Form 2252 documents for each distinct application number even if the products are related. For example, if a company holds both an NDA and a BLA for different products, each requires its own annual report with its own Form 2252, even if submitted on the same date.

Pros and Cons of the Form 2252 System

The Form 2252 requirement serves important regulatory purposes but also creates compliance burdens. Understanding both aspects provides perspective on the system’s role.

Pros

Standardized information architecture improves FDA efficiency. Form 2252’s structured format ensures FDA receives consistent information across all annual reports. Reviewers can quickly locate specific data types (distribution volumes, manufacturing changes, safety updates) without searching through varied report formats, reducing review time and improving regulatory decision speed.

Annual tracking prevents compliance drift over time. The mandatory annual submission creates recurring checkpoints where companies must assess safety data, manufacturing quality, and postmarketing study progress. This structured cadence prevents companies from losing focus on postmarketing obligations after the excitement of initial approval fades.

Electronic validation catches errors immediately. eCTD validation performed during ESG submission identifies technical errors in real-time, allowing correction before FDA reviewers expend effort on deficient submissions. This reduces wasted review resources and provides applicants faster feedback on submission adequacy.

U.S. agent requirements facilitate international commerce. By mandating U.S. agent designation for foreign manufacturers, the system creates clear communication channels between FDA and international companies. This supports global pharmaceutical trade while ensuring FDA maintains effective regulatory oversight of foreign-manufactured products entering U.S. commerce.

PMR/PMC tracking enhances patient safety. The requirement to report postmarketing study status annually creates transparency about whether safety and efficacy questions identified during approval are being adequately addressed post-approval. This protects patients from products whose benefit-risk profiles may change as additional evidence emerges.

Cons

Administrative burden diverts resources from innovation. Pharmaceutical companies must allocate significant personnel time to compiling annual reports and completing Form 2252 correctly. For companies with large product portfolios, this creates substantial administrative overhead that could otherwise support research and development activities.

Rigid deadlines create compliance risk for minor delays. The strict 60-day anniversary deadline allows no flexibility for circumstances beyond company control, such as corporate restructuring, natural disasters, or sudden key personnel departures. Missing the deadline by even one day constitutes a violation subject to enforcement action regardless of mitigating circumstances.

Technical validation errors cause disproportionate impacts. Minor technical errors like incorrect date formatting or file naming conventions trigger complete submission rejection through eCTD validation. The requirement to correct and resubmit consumes time and can push submissions past deadlines even when the substantive content was adequate.

Form revisions require system updates. When FDA updates Form 2252 or changes eCTD specifications, companies must modify their electronic submission systems, retrain staff, and update internal procedures. For large pharmaceutical companies with automated submission workflows, these changes require substantial IT investment and validation effort.

Duplicate reporting creates information overload. Information required in annual reports often overlaps with other FDA submissions including periodic safety reports, field alert reports, and manufacturing supplements. Companies question whether FDA effectively integrates information across submission types or whether the agency struggles with information overload from duplicative data streams.

State-Level Considerations and Federal Primacy

While Form 2252 operates under federal law, understanding the relationship between federal and state pharmaceutical regulation provides important context.

Federal Regulatory Authority

The Federal Food, Drug, and Cosmetic Act vests primary authority for drug approval and postmarketing oversight in FDA. Once a drug receives federal approval, the NDA, ANDA, or BLA holder must comply with federal reporting requirements including Form 2252 annual report submissions.

States cannot impose additional or different annual reporting requirements that conflict with federal law. Under the Supremacy Clause of the U.S. Constitution, federal law preempts state law when both regulate the same activity and conflict exists.

This means California, New York, or any other state cannot require separate annual reports with different content or timelines that contradict FDA requirements. The federal Form 2252 submission satisfies the annual reporting obligation nationwide.

State Authority Boundaries

States retain authority over matters not preempted by federal law. States can regulate pharmacy practice, wholesale drug distribution within their borders, and certain aspects of drug marketing and sales.

Some states require pharmaceutical manufacturers to register within the state and report certain business information like pricing data, marketing expenditures, or charitable contributions. These state requirements operate parallel to federal requirements rather than conflicting with them.

Manufacturers must comply with both the federal Form 2252 annual report to FDA and any separate state business registration or reporting requirements. The key distinction is that state requirements cannot alter or substitute for federal annual reporting obligations.

Multi-State Operations

For companies manufacturing at multiple sites across different states, the Form 2252 requirement remains singular and federal. A company operating manufacturing facilities in New Jersey, California, and Puerto Rico files one Form 2252 per application to FDA covering all sites listed in the approved application.

State inspectors may audit manufacturing facilities for compliance with state pharmacy laws, but these inspections do not alter federal annual reporting requirements. Companies should maintain documentation of state compliance separately from federal annual reports.

Enforcement and Penalties for Non-Compliance

Understanding enforcement consequences motivates timely and accurate Form 2252 submissions. FDA maintains several enforcement tools for annual reporting violations.

Warning Letters and Untitled Letters

FDA issues warning letters for violations of the Federal Food, Drug, and Cosmetic Act that may lead to enforcement action. Failure to submit annual reports with Form 2252 within the required timeframe can trigger warning letters.

Warning letters become public documents posted on FDA’s website, creating reputational damage. The letters identify specific violations, demand corrective action within 15 business days, and warn that failure to correct deficiencies may result in seizure, injunction, or criminal prosecution.

Untitled letters address violations that do not meet warning letter criteria but still require corrective action. While less severe than warning letters, untitled letters still document regulatory non-compliance and can escalate to warning letters if violations persist.

Application Withdrawal

For products approved under accelerated approval provisions, failure to complete required postmarketing studies creates grounds for approval withdrawal. If annual reports do not document adequate progress on PMRs or if applicants fail to submit the required Form 2252 tracking study status, FDA can initiate withdrawal proceedings.

Under 21 CFR 314.530, FDA may withdraw accelerated approval if the applicant fails to conduct required postmarketing studies with due diligence, the postmarketing study does not verify clinical benefit, or other evidence demonstrates the drug is not safe or effective under conditions of use.

The withdrawal process involves issuing a notice of opportunity for hearing. If the applicant cannot demonstrate adequate progress or clinical benefit, FDA withdraws approval and the product must be removed from the market.

Civil Monetary Penalties

Although FDA rarely assesses civil monetary penalties specifically for Form 2252 violations, the agency has authority to impose fines for violations of the Federal Food, Drug, and Cosmetic Act.

Under 21 USC 333, violations can result in fines up to $250,000 per individual or $500,000 per corporation for each offense. Repeat violations within the same three-year period can result in imprisonment up to three years.

For violations related to clinical trial reporting obligations that parallel the annual report requirements, FDA has assessed civil monetary penalties exceeding $350,000 for failure to submit required information. This demonstrates the agency’s willingness to use financial penalties for reporting violations.

Consent Decrees and Injunctions

For systemic compliance failures including repeated annual reporting violations, FDA can seek injunctive relief through federal court. An injunction requires the company to take specific corrective actions and often involves court-appointed monitors overseeing compliance.

Consent decrees represent negotiated agreements between FDA and companies to resolve serious violations without trial. Consent decrees typically require comprehensive compliance program overhauls, independent audits, and regular reporting to demonstrate sustained compliance.

Impact on Future Applications

Companies with histories of annual reporting violations face increased scrutiny on future applications. FDA reviewers consider an applicant’s compliance history when assessing new NDAs, ANDAs, or BLAs.

Poor compliance records can lead to pre-approval inspections with expanded scope, delayed approval decisions pending resolution of compliance issues, and refusal to approve new applications until existing violations are corrected. This creates significant business impact beyond the direct penalties for individual violations.

Recent Regulatory Updates and Future Trends

The Form 2252 system continues evolving as FDA modernizes its electronic submission infrastructure and reporting requirements.

eCTD Version 4.0 Transition

FDA began accepting eCTD version 4.0 submissions for new applications on September 16, 2024. This represents a significant technical upgrade from version 3.2.2, incorporating improved metadata standards, enhanced validation rules, and better integration with FDA’s electronic review systems.

Form 2252 must be submitted within the eCTD 4.0 structure using updated specifications. Applicants planning to use version 4.0 should consult the FDA Data Standards Catalog for technical requirements and ensure their submission systems support the new format.

FDA has announced that eventually only eCTD 4.0 will be accepted, requiring all applicants to transition from version 3.2.2. The agency will provide advance notice of when version 3.2.2 support ends, but companies should begin planning the transition now to avoid rushed implementation.

Structured Product Labeling Integration

FDA continues expanding requirements for structured product labeling (SPL) in electronic format. Annual report labeling submissions increasingly leverage SPL format, which provides machine-readable labeling information that integrates with FDA’s public databases.

Form 2252 submissions must account for SPL requirements when reporting labeling changes. Companies submitting updated labels in the annual report should ensure consistency between human-readable PDF versions and structured SPL files.

Enhanced PMR/PMC Tracking

FDA has invested significant resources in improving postmarketing study tracking systems. The public PMR/PMC database provides searchable information on all postmarketing studies and trials.

Form FDA 3989, introduced to standardize PMR/PMC status reporting, represents FDA’s push toward structured data collection that populates these tracking databases automatically. Applicants should expect continued emphasis on accurate, timely Form 3989 submissions as part of the annual report transmitted by Form 2252.

Real-Time Reporting Considerations

Industry stakeholders have raised questions about whether annual reporting adequately addresses safety concerns that emerge throughout the year. FDA has enhanced requirements for expedited field alert reports and periodic adverse event reports separate from the annual report cycle.

While Form 2252 annual reports remain the primary vehicle for comprehensive yearly updates, companies increasingly face expectations for real-time reporting of significant safety issues. Future regulations may adjust the balance between scheduled annual reporting and event-driven reporting obligations.

FAQs

Can I submit Form 2252 electronically?

Yes. Electronic submission through FDA’s Electronic Submission Gateway using eCTD format is now required for most NDAs, ANDAs, and BLAs per 21 USC 745A(a).

Does Form 2252 apply to over-the-counter drugs?

Yes. All approved NDAs require Form 2252 with annual reports regardless of prescription or OTC status, as mandated by 21 CFR 314.81(b)(2).

What happens if I miss the 60-day deadline?

Violation recorded. FDA documents the late submission as a violation of 21 CFR 314.81, which may trigger warning letters and impact future applications.

Can one Form 2252 cover multiple applications?

No. Each distinct application number requires its own Form 2252 transmittal form even if products are related or reports submitted simultaneously.

Do I need Form 2252 if my product is discontinued?

Yes. Annual reporting continues for all approved applications until FDA formally accepts an application withdrawal request under 21 CFR 314.150.

Who can sign Form 2252 for foreign companies?

U.S. agent required. Foreign applicants without U.S. business locations must have a U.S. agent with physical U.S. presence sign per 21 CFR 314.50(a)(5).

Is Form 2252 required for generic drugs?

Yes. All approved ANDAs require annual Form 2252 submissions within 60 days of ANDA approval anniversary under 21 CFR 314.81(b)(2).

Can I revise Form 2252 after submission?

Resubmit entirely. Submit a corrected complete eCTD package with revised Form 2252 using the same sequence number if FDA rejects original submission.

Does Form 2252 replace Form 356h?

No. Form 2252 transmits annual reports while Form 356h covers initial applications and supplements, serving completely different regulatory functions.

What if I have no changes to report?

Still required. File Form 2252 with annual report even if “None” appears in multiple field categories, as submission itself demonstrates ongoing compliance.

Are BLA requirements identical to NDA requirements?

Mostly similar. BLA holders use Field 11 instead of Field 10 for postmarketing studies per 21 CFR 601.70, but timing and submission format remain consistent.

How long should I retain Form 2252 records?

Minimum two years. FDA regulations require retaining application records for two years post-approval discontinuation, though companies often maintain records longer for legal protection.